Skip to content

Phase 1 Trial of Tris-hydroxymethyl aminomethane (THAM) Infusion on the dyspnea associated with Cancer

Phase 1 Trial of Tris-hydroxymethyl aminomethane (THAM) Infusion on the dyspnea associated with Cancer - Phase 1 Trial of Tris-hydroxymethyl aminomethane (THAM) Infusion on the dyspnea associated with Cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000005854
Enrollment
12
Registered
2011-07-01
Start date
2011-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyspnea associated with Cancer

Interventions

THAM infusion at a rate of 0.2ml/kg/min for 20 min or 40 min

Sponsors

Chiba University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: I. The first stage 1) Age >= 20 2) Notified cancer patients 3) The patients having cancer dyspnea mainly caused by one of the following conditions: pleural effusion, ascites, primary lung tumor, metastatic lung tumor, cough, air way stenosis, and phrenic nerve paralysis, with or without chronic obstructive lung disease II. The second stage 1) Written informed consent 2) The patients with the sensation of dyspnea, the worst score of which is 6 or more on NRS, on 2 consecutive days 3) Expected survival of more than 2 weeks 4) The patients with the sensation of dyspnea after the treatment of rapid onset oral morphine 5) PS(ECOG)1-3 6) Hospitalized patients 7) Eligible for the first stage inclusion criteria

Exclusion criteria

Exclusion criteria: I. The first stage 1) Hypersensitivity reactions to THAM and opioids 2) Severe heart failure, respiratory disease with unstable dyspnea 3) Neurological, mental impairment with the difficulty of collecting data 4) Drug abuse, drug dependence 5) Pregnancy, lactation II. The second stage 1) Inability to take oral rapid onset morphine 2) Pain score above 3 3) Severe hypertention(SBP >= 180mmHg or DBP >= 110mmHg) 4) Liver failure, renal failure AST(GOT) >= 100IU/L ALT(GPT) >= 100IU/L T.bil >= 2.0mg/dL eGFR <= 30 mL/hr 5) Metabolic or respiratory acidosis 6) Severe respiratory failure or the administration of oxygen with flow rate of 10L/min or more 7) Ineligible condition for study in physician's judge 8) The change in prescription of opioids, steroids and anxiolytics within 2 days prior to study 9) The change in the chemotherapy within 7 days prior to study 10) SBP <= 90mmHg, SpO2 < 90%, RR at rest <= 10, BS < 60

Design outcomes

Primary

MeasureTime frame
Respiratory depression, hypotention, hypoglycemia and adverse effects greater than grade 3 on CTCAE ver 4.0

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026